Yes, torsemide is a loop diuretic.
Torsemide is definitively classified as a loop diuretic that inhibits sodium and chloride reabsorption at the loop of Henle, alongside bumetanide and furosemide 1.
Mechanism of Action
Torsemide works by inhibiting the Na+-K+-2Cl- cotransporter in the ascending loop of Henle in the kidneys 2. This mechanism is identical to other loop diuretics like furosemide and bumetanide, distinguishing it from:
- Thiazide diuretics (e.g., hydrochlorothiazide, metolazone) which act at the distal convoluted tubule
- Potassium-sparing diuretics (e.g., spironolactone) which act at the collecting duct 1
Clinical Positioning
According to the 2022 AHA/ACC/HFSA Heart Failure Guidelines, loop diuretics are the preferred diuretic agents for use in most patients with heart failure 1. The guidelines explicitly list torsemide in Table 12 under "Loop diuretics" with:
- Initial daily dose: 10-20 mg once
- Maximum total daily dose: 200 mg
- Duration of action: 12-16 h 1
Pharmacological Advantages
Torsemide offers several distinct advantages over furosemide:
- Higher oral bioavailability - more reliable absorption 1, 2
- Longer half-life and duration of action (12-16 hours vs 6-8 hours for furosemide) 1, 2
- Once-daily dosing capability 3
- Potential anti-aldosterone effects 2
Clinical Outcomes
While torsemide and furosemide demonstrate equivalent volume control and mortality outcomes, torsemide is associated with reduced heart failure readmissions (OR 2.16 for furosemide vs torsemide) and improved NYHA functional class 4. Some patients respond more favorably to torsemide than furosemide, potentially due to increased oral bioavailability 1.
Important caveat: Torsemide is a substrate of CYP2C9, requiring dose adjustments when used with CYP2C9 inhibitors (amiodarone, fluconazole) or inducers (rifampin) 5.